<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368221</url>
  </required_header>
  <id_info>
    <org_study_id>35RC20_8885_MY_CO_VID</org_study_id>
    <nct_id>NCT04368221</nct_id>
  </id_info>
  <brief_title>Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU</brief_title>
  <acronym>MY-CO-VID</acronym>
  <official_title>Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterization of fungal infections in COVID-19 infected and mechanically ventilated
      patients in ICU
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, ICU patients with ARDS, whatever the etiology, are not systematically screened for
      the detection of respiratory fungal infections.

      Here, the protocol will be in two steps:

      First step

      COVID-19 patients hospitalized in ICU for ARDS will benefit for a systematic screening with a
      fungal respiratory syndromic panel once or twice a week from entry to discharge from ICU,
      with minimum 3 samples when discharge occurs after 15 days::

        -  Sample: tracheal aspiration, bronchial aspiration, BAL

        -  Fungal respiratory panel: samples will be processed in each lab for culture without
           direct examination nor stained smears, and real-time PCR will be performed for
           Aspergillus, Pneumocystis jirovecii and mucormycetes

        -  Results will be given to ICU in order to optimize the management of the patient Second
           step

      Complementary analysis will be performed in order to finalize the diagnostic and to
      differentiate between colonization and infection, with:

        -  Serum detection of galactomannan and serum Aspergillus PCR in case of positive
           respiratory sample for Aspergillus

        -  Serum/plasma beta-D-glucan detection in case of positive respiratory sample for
           Pneumocystis jirovecii

        -  Serum mucorales PCR in case of positive respiratory sample for mucorales This second
           step is possible in most of the labs, but when necessary a confirmation test can be
           externalized. A process of DNA transmission to a reference lab within each region will
           be implemented.

      This second step will allow to classify infections as probable or proven according to
      international recommendations.

      Case report form (CRF) A short but standardized CRF will be proposed to all centers in order
      to collect demographic data and the essential clinical and laboratory data during the survey.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Opportunistic fungal co-infections.</measure>
    <time_frame>at 12 months</time_frame>
    <description>Prevalence of opportunistic fungal co-infections.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time</measure>
    <time_frame>at 12 months</time_frame>
    <description>Determination of the median time between entry in ICU and beginning of ARDS and (i) colonization and (ii) probable/proven infection with Aspergillus, Pneumocystis jirovecii and mucormycetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between diagnosis and targeted treatment</measure>
    <time_frame>at ICU discharge, up to 1 month</time_frame>
    <description>Evaluation of the time between diagnosis and targeted treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preventive strategies</measure>
    <time_frame>At 12 months</time_frame>
    <description>Number of proposals for evaluation of preventive strategies if necessary, because of high incidence, in terms of chemoprophylaxis and/or environmental measures</description>
  </secondary_outcome>
  <enrollment type="Actual">576</enrollment>
  <condition>Covid-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in ICU for COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  ICU patients COVID-19 diagnosed by RT-PCR

          -  Intubated and mechanically ventilated patients

          -  Adult patients

          -  Patients (or family or legal representative) informed on the research without
             opposition

        Non-inclusion criteria :

          -  Patients &lt;18 years old

          -  People of full age who are the subject of a judicial safeguard,

        Exclusion criteria:

          -  Patient, relative or legal representative opposing the pursuit of the research

          -  Patients under judicial protection will be excluded as soon as the investigator
             becomes aware of their status.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Avicenne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière/ St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Invasives mycoses</keyword>
  <keyword>aspergillosis</keyword>
  <keyword>pneumocystosis</keyword>
  <keyword>mucormycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

